PNGAF Precision Peptide Company Inc. (The)

$PNGAF $HIMS $TRLV A health product can exist long before it becomes easy for consumers to access. Developing the product is only one part of the equation. Patients and consumers still need a practical way to learn about it, determine whether it is appropriate for them, obtain it through the proper channel and use it in a format that fits into everyday life. That last part of the healthcare system—the route between a product and the end user—is changing quickly. Hims & Hers Health Inc. (NYSE: HIMS) has built much of its business around bringing healthcare evaluation, prescribing and fulfillment into a digital environment. Trulieve Cannabis Corp. (NYSE: TRLV) operates in a highly regulated category that has historically relied on specialized dispensary networks but is beginning to appear in more conventional medical distribution settings in certain states. The Precision Peptide Company (CSE: BPC; OTCQB: PNGAF) is approaching access from another direction, combining direct-to-consumer and wholesale distribution with alternative delivery formats such as transdermal patches. The products and regulatory frameworks are different. What connects the three companies is the growing importance of how healthcare and wellness products actually reach the consumer.